GRAIL, Inc. has secured $325.0 million in private placement financing to support its cancer detection mission, with lead investor Morgan Stanley. The funding will aid in commercial activities and working capital.
Goldman Sachs & Co. LLCBraidwell LPDeep Track CapitalFarallon Capital ManagementHims & HersMorgan Stanley
Description
GRAIL, Inc. announced a securities purchase agreement for a private placement expected to yield approximately $325.0 million. The offering has participation from both new and existing institutional investors, led by Morgan Stanley. Proceeds will be used for commercial activities, reimbursement efforts, and general corporate purposes
Company Information
Company
Grail
Location
1525 O'Brien Drive
Menlo Park, California, United States
About
Grail is a healthcare company focused on the early detection of cancer through its innovative liquid biopsy technology. The company aims to transform cancer diagnosis and treatment by providing tools that detect cancer at its earliest stages. Grail's mission is to help save lives through early cancer detection. The firm blends cutting-edge genetic science with next-generation sequencing.
Fundz sees it the moment Grail raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Menlo ParkBiotechnologyHealth CareGeneticsHealth Diagnosticsresearch